BioSpace News Archive

Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference.

NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), today announced that Laurent Levy, Chief Executive Officer, will present the Company’s latest corporate and clinical developments during a webcast at the virtual H.C. Wainwright 23rd Annual Global Investment Conference.

AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chief Executive Officer of AzurRx, will present virtually at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, announced that senior management will participate in fireside chats at two upcoming virtual investor conferences.

Puma Biotechnology, Inc., a biopharmaceutical company, announced that on September 1, 2021, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 16,375 shares of Puma common stock to three new non-executive employees.

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda’s management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021.

Ultragenyx Pharmaceutical Inc. announced that Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer and President will present at the Morgan Stanley 19th Annual Healthcare Conference on September 14, 2021 at 4:15 PM ET.

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced the final overall survival (OS) results of the SOPHIA Phase 3 study in adult patients with metastatic HER2-positive breast cancer.

Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.

Ascendis Pharma A/S, a biopharmaceutical company that utilizes its innovative TransCon™ technologies to potentially create new treatments that make a meaningful difference in patients’ lives, announced that the company will participate in two upcoming investor conferences.